Alkem Laboratories (ALKEM) Fundamentals 2026 — P/E 29.0x, Revenue Analysis | SniperIQ
Alkem Laboratories (ALKEM) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹66,812 Crore, trading at ₹5588.75 on the BSE. This SniperIQ fundamentals page covers Alkem Laboratories's valuation (P/E 29.0x, P/B 4.8x), profitability (net margin 15.6%), revenue (₹14,712 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Alkem Laboratories's market cap?
Alkem Laboratories (ALKEM) has a market capitalization of approximately ₹66,812 Crore, trading at ₹5588.75 on the BSE. Market cap moves with the live share price.
What is Alkem Laboratories's P/E ratio?
Alkem Laboratories's trailing twelve-month P/E ratio is 29.0x, with a price-to-book (P/B) of 4.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Alkem Laboratories?
Alkem Laboratories runs a net profit margin of 15.6%, a gross margin of 65.4%, and an operating margin of 17.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Alkem Laboratories generate?
Alkem Laboratories reported revenue of ₹14,712 Crore for fiscal year 2026, with net income of ₹2,302 Crore and earnings per share (EPS) of 192.51. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Alkem Laboratories pay a dividend?
Alkem Laboratories offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Alkem Laboratories financially healthy?
Alkem Laboratories carries a debt-to-equity ratio of 0.15x and a current ratio of 2.55x, with a market beta of 0.27. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Alkem Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alkem Laboratories (ALKEM) the key facts are: market cap ₹66,812 Crore, P/E 29.0x, revenue ₹14,712 Crore, 52-week range 4740.65-5933. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Alkem Laboratories's full fundamentals live
Get Alkem Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.